Novartis shares have risen over 20% in the past 6 months, making it the best-performing global pharmaceutical stock. Find out ...

When high levels of low-density lipoprotein cholesterol (LDL-C or bad cholesterol) are untreated for a long time, they lead ...

Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop ...

Novartis (SIX:NOVN), and other stocks could present surprises to investors during the third quarter earnings season, as per analysts at UBS. The analysts flag several key factors that could influence ...

Generate could receive more than $1bn in performance-based milestone payments, in addition to royalty payments.

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...

Biomedicines’ generative artificial intelligence (AI) platform to discover and develop protein therapeutics for multiple ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

“Novartis India Limited vide its communication dated 1 7th February 2024 informed BSE about a communication received from ...

Generate:Biomedicines, a Flagship Pioneering company using artificial intelligence to create new medicines, announced today that it has struck a deal with Novartis to develop an undisclosed number of ...

Sources have also said that non-binding bids have been submitted, and both companies are currently engaged in advanced round ...

Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.